Octapharma Gains FDA Supplemental Approval for FIBRYGA Fibrinogen Concentrate in Acquired Deficiency

A supplemental approval issued by FDA on June 23, 2025 expands the labeled indications for Octapharma's FIBRYGA (Fibrinogen Human), adding fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency to an existing indication covering congenital deficiency states. For plasma-derived biologics manufacturers, the approval adds a commercially active product to the regulatory landscape governed by 21 CFR Part 640, with attendant implications for lot release testing protocols and donor plasma screening documentation.

FIBRYGA (STN# 125612), manufactured by OCTAPHARMA Pharmazeutika Produktionsges.m.b.H., was originally approved in June 2017 under the tradename FIBRYNA before transitioning to its current designation. The June 2025 supplemental letter follows a July 31, 2024 approval letter and accompanying clinical and statistical review memos, indicating a multi-cycle review process that QA directors at contract plasma fractionators should note when benchmarking their own submission timelines for comparable biologics license applications.

The approved indications now cover two distinct patient populations: those presenting with acute bleeding episodes in the setting of congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia, and those with acquired fibrinogen deficiency secondary to bleeding events. One limitation of use is explicitly preserved: FIBRYGA remains contraindicated for dysfibrinogenemia, a qualitative rather than quantitative deficiency, which carries downstream consequences for clinical protocol design and labeling compliance reviews.

For regulatory affairs leads managing plasma-derived product portfolios, the supporting document package, which includes a Clinical Pharmacology Supplemental Review and a Demographic Subgroup Information document cross-referenced to Section 1.1 of the clinical reviewer memo, signals FDA's continued expectation of subgroup outcome analyses in biologics submissions. Manufacturers preparing supplemental BLAs for similar plasma fractions should treat the FIBRYGA dossier structure as a current reference point for clinical and statistical review alignment under ICH Q10-aligned quality systems.

The approval history spanning 2017 through 2025 also reflects the iterative nature of post-approval commitments for plasma-derived biologics, a trajectory that GMP-compliant manufacturers should factor into lifecycle management planning and change control documentation under 21 CFR Part 211.

The June 23, 2025 approval letter and full supporting document set are publicly accessible on the FDA Approved Blood Products page, providing a concrete reference for sterility assurance and lot release benchmarking against a currently licensed fibrinogen concentrate.

Source: FDA Vaccines, Blood and Biologics / Approved Blood Products page via RSS feed, July 8, 2026.